Owners
History
2026: NTI Sovereign Technology Fund buys stake in Brainfon
In January 2026, the Sovereign Technology Fund (FST NTI) and the Tramplin Ventures venture fund acquired a stake in Brainfon, which develops AI technologies for diagnosing brain diseases. Investments were made through an increase in the authorized capital, their volume was not disclosed.
According to CNews, according to the results of the deal, FST NTI and Tramplin Venture received 11.99% each in the authorized capital of the startup. The controlling stake of 76.02% was retained by the co-founder of the project, Candidate of Medical Sciences Diana Hasanova.
Brainfon specializes in creating artificial intelligence technologies to identify neurodegenerative diseases such as dementia and Parkinson's disease by analyzing a patient's voice and speech. This method is a non-invasive and potentially scalable screening tool.
Elena Vatutina, General Director of the PharmKnowledge analytical platform, noted the value of such projects for the state. Ildar Sattarov, head of the Alliance for Advanced Technologies, adds: traditional diagnosis of brain diseases requires significant time and money, while screening using AI can be 10-50 times cheaper.
To reach the stage of a mature product, medical technology projects (Medtech) need investments in the amount of 80 to 150 million rubles. The main costs are not related to the development of the algorithm, but to the collection of clinical data, conducting thorough research, obtaining regulatory approvals and integration into the medical infrastructure.
Ildar Sattarov explained that the support of state funds, such as FST NTI, provides projects with a "regulatory tunnel" - accelerated passage of the necessary tests and access to the infrastructure of clinics.[1]
Notes
| | The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |
